Previous studies had not excluded the possibility that the mechanism by which Xenon (Xe) blocks N-methyl-D-aspartate (NMDA) receptors might be that of an openchannel blocker. We tested this possibility on mutant NMDA receptors carrying an alanine (A) to cysteine (C) mutation located within the SYTANLAAF-motif of the third transmembrane region (TM3). This mutation was shown to yield constitutively open ion channels after modification with a thiol-modifying reagent. We expressed such mutant channels in Neuro2A cells and recorded glutamate (50 µM)-induced currents in the whole-cell recording mode. While Xe (3.5 mM) blocked the currents through the wild-type receptor NR1-1a/NR2A and NR1-1a/NR2B by about 40% and those through the mutant receptors NR1-1a/NR2A(A650C) or NR1-1a/NR2B(A651C) by about 30%, it was unable to block the currents through the methane thiosulfonate 
Introduction
Although the NMDA receptor has long been known to be a molecular target for Xe (Franks et al., 1998) , the knowledge as to how the noble gas interacts with this ion channel is still scarce. Several groups have shown that Xe interacts with glutamate receptors in a non-competitive manner, indicating that Xe might bind to the receptor apart from the ligand binding site (Franks et al., 1998; Dinse et al., 2005) . In the case of ion channels, the term "non-competitive" also includes sites located within the channel pore. Indeed, we and others found hints which led to the speculation that Xe might interact with glutamate receptors by a channel blocking mechanism (Dinse et al., 2005; Colloc'h et al., 2007) . Others, however, have disclaimed this speculation (deSousa et al., 2000) .
In search of an appropriate approach to substantiate or discard these speculations we went back to previous studies in which the substituted cysteine accessibility method was used to identify residues within NMDA receptors lining the channel-pore or structural elements coupling ligand binding with channel opening (Beck et al., 1999; Jones et al., 2002; Sobolevsky et al., 2002a) . In these studies, multiple cysteine substitutions within the highly conserved 9 amino-acid motif SYTANLAAF at the C-terminal end of TM3, partly forming the extracellular vestibule of the ion channel pore, have been investigated. A single cysteine (C) substitution of alanine (A) at position 7 (A-7-C) showed unique properties as it revealed constitutive open channels after modification with the thiol-modifying reagent MTSEA. This covalent modification occurred only in the presence of the agonists glutamate and glycine, indicating that this process required the activation of the ion channel. After removal of both the modifying reagent and the agonists, the channels stayed open. Yuan et al tested this mutant with different blockers and found that the modified channels were insensitive to competitive antagonists and less sensitive to allosteric modulators, but retained their sensitivity to open channel blockers, although the effects varied depending on the presence or absence of agonists (Yuan et al., 2005) . Taking advantage of this particular receptor mutant, we were able to address the question whether Xe is capable of blocking open NMDA receptor ion channels directly.
Materials and Methods
The neuroblastoma cell line Neuro2A (ATCC#CCL 131) was used for transient transfection. The cells were cultured at 37°C in a humidified atmosphere of 95 % air and 5 % CO 2 in DMEM, supplemented with 2 mM L-glutamine (Boehringer, Mannheim, Germany), 10 % (v/v) fetal calf serum (Gibco, Eggenstein, Germany), 50 U penicillin/ml and 50 µg/ml streptomycin (Gibco) on polyornithine-coated culture dishes. After the cells had reached 40 % confluency, they were transfected with the cDNAs encoding NMDA receptors. For wild-type receptors, the rat NR1-1a subunit (Moriyoshi et al., 1991) GeneBank accession number (NM_017010) was combined either with the mouse NR2A (NM_008170), the mouse NR2B (NM_008171), the rat NR2C (M91563) or the rat NR2D (L31611) subunit. In order to achieve constitutively open channels, NR1-1a wild-type subunits were combined with the NR2A(A650C) or the analogous NR2B(A651C) mutant (A-7-C) which had alanine (A) at position 7 within the SYTANLAAF-motif substituted for cysteine (C). The mutant channels were then modified by co-application of MTSEA (0.4 mM), glutamate (50 µM) and glycine (10 µM) for two minutes. The substitutions were engineered using the Stratagene quickchange site-directed mutagenesis kit and confirmed by sequence analysis (Stratagene, Amsterdam, The Netherlands). Cysteine substitutions were also performed at the adjacent sites to position 7 (L-6-C and A-8-C). These were NR2A(L649C), NR2A(A651C), NR2B(L650C) and NR2B(A652C).
For experimentation, the cells were rinsed with extracellular solution composed of (in mM): 140 NaCl, 2.7 KCl, 1.5 CaCl 2 , 10 glucose and 12 HEPES; pH 7.3. Glutamateevoked membrane currents were determined in the whole-cell recording mode (Hamill et al., 1981) using an EPC-9 amplifier and TIDA software (HEKA, Lambrecht, Germany). Patch pipettes were drawn from borosilicate glass. Their tip resistances were between 3-6 M when filled with (in mM) 140 CsCl 2 , 2 MgCl 2 , 2 ATPx2Na, 2 EGTA, 10 HEPES; pH 7.2. Xe-containing solutions were prepared as previously described (Dinse et al., 2005) . We did not analyze concentration-response relationships for Xe as even with the maximal concentration of Xe as used here the glutamate activated currents were only blocked by about 40 % (Weigt et al., 2003) .
The receptor agonists were applied to the cells using the L/M-SPS-8 superfusion system (List, Darmstadt, Germany). To restrict the presence of the agonists to a small volume within the dish, a combination of two perfusion systems was installed, i.e., (i) a global bath perfusion with the inflow set at 4.5 ml/min and an outflow that removed any excess fluid, and (ii) a local inlet for the generation of a continuous stream of test solution. For a quick change between various test solutions the local inlet consisted of the tip of an eight-barrelled pipette that was positioned at a distance of 50-100 µm upstream of the measuring field. All test solutions were administered at 1 ml/min using infusion pumps (Braun, Melsungen, Germany). For the pre-application of Xe, an additional inlet, positioned 50 to 100 µm upstream from the measuring field, was used. The time of solution exchange was estimated from the changes in the liquid junction potential to be about 1 ms.
Results and Discussion
The current responses to 5-s pulses of 50 µM glutamate and 10 µM glycine to NR1-1a/NR2A and NRNR1-1a/NR2B receptors expressed in Neuro2A cells were characterized by a fast peak followed by a slow decline which tended to a plateau at the end of agonist application (Fig. 1A, C) . In the presence of Xe both, peak and plateau currents of NR1-1a/NR2A receptors were reduced by 37.5 ± 6.2 and 38.0 ± 8.1 %, respectively (n= 8 cells). The corresponding values for NR1-1a/NR2B were 42.0 ± 3.3 and 43.1 ± 10.7 % (n = 6 cells). These results are in accordance with previous measurements at heterologous expressed NMDA receptors (Yamakura and Harris, 2000; Ogata et al., 2006) . When the A-7-C receptor mutants NR2A (A650C) and NR2B(A651C) were analyzed in the same manner, the resulting currents were predominantly small. A consistently smaller current amplitude for these mutant receptors was also described in a previous report although the EC50s for glutamate obtained for wild-type and mutant receptors were not significantly different (Yuan et al., 2005) . The mutant but un-modified NMDAR channels were also blocked by Xe, the reduction of peak and plateau currents being 33.6 ± 6.7 and 36.2 ± 6.1 % at NR1-1a/NR2A(A650C) and 34.9 ± 6.7 and 32.7 ± 9.5 % at NR1-1a/NR2B(A651C), respectively (n=8; Fig. 1 B, D) .
When the NR1-1a/NR2A(A650C) and the NR1-1a/NR2B(A651C) receptor mutants were treated with MTSEA (0.4 mM) in the presence of agonists (50 µM glutamate / 10 µM glycine) the current amplitude continuously increased, indicating channel modification. As these modified channels can only be closed by open channel blockers (Yuan et al., 2005) , we used Mg 2+ (1 mM) for this purpose. Upon washout of Mg 2+ the channels reopened even without application of agonists. As shown in Fig. 2 , Xe blocked the mutated channel (see also Fig. 1 ), however it was completely unable to block the MTSEA-modified channels. Of note, the current amplitude upon washout of Mg 2+ exceeded that obtained before in the presence of MTSEA and agonists. This increase in current amplitude reveals an additional property of MTSEA, namely to act by itself as an open-channel blocker at NMDA receptors (Jones et al., 2002) .
In a previous report Yuan and collegues compared the inhibitory potency of MK801-and Mg 2+ to block the mutated and modified channels in the absence and presence of agonists (Yuan et al., 2005) . While Mg 2+ ions were equally effective under both conditions, MK-801 preferentially blocked the modified channels in the absence but not in the presence of the agonists. In order to test whether the latter attitude might also apply to Xe we compared the inhibitory capacity of Xe in the presence and absence of the agonists. It turned out, that Xe is unable to block the mutated and modified ion channels irrespective whether the agonists are present or not (Fig. 3 ).
As the current of the NR2A(A650C) mutant unlike that of the NR2B(A651C) mutant had a tendency to decline in the absence of agonists, we extended the time for Xe application from 10 sec (see right part of Fig. 2 ) to 30 sec in order not to miss a slow occuring effect of Xe. Also under these conditions we could not detect an inhibitory effect of Xe as the decline was the same in the presence and absence of Xe.
To analyze whether above observations are specific for position 7, we established additional cysteine substitutions at postion 6 and 8 (L-6-C and A-8-C) of the NR2A and the NR2B subunits. As the current amplitudes of the L-6-C mutants on either subunit were unresolvable, we did not include these mutants in our study. The current amplitudes of the A-8-C mutants were rather small and inhibition by Xe was 34.5 ± 4.7% for NR2A(A651C) and 41.8 ± 8.7 % for NR2B(A652C) (n = 4 to 7 cells).
In contrast to the A-7-C mutants, the A-8-C mutants did not undergo modification and
Xe sensitivity was the same before and after MTSEA application (not shown).
As all NMDA receptors contain several extracellular cysteines (Jones et al., 2002) , we also investigated the effect of MTSEA in the wild-type receptors. Co-application of MTSEA and agonists did not evoke a continuous increase of the current amplitude, indicating that the wild-type receptor was not modified in the same manner as the mutant receptor. However, the inhibitory potency of MTSEA was evident as can be deduced from the diminished current amplitude obtained by co-application of MTSEA and agonists versus application of agonists alone (Fig. 4) . These results are in agreement with a previous report demonstrating a reversible inhibition of NMDA wildtype receptors by MTSEA (Jones et al., 2002) . However, in contrast to the mutant receptor, the Xe sensitivity was the same before and after application of MTSEA (Fig.   4) . Thus, even when MTSEA modified other cysteines within NMDA wild-type receptors it did not abolish the sensitivity to Xe, indicating that the introduced and modified cysteines at position 7 of the SYTANLAAF motif are crucial for the abolition of the Xe sensitivity.
Since the inhibitory effect of Xe is completely abolished at the A-7-C mutants after to have a weaker effect on NR2D containing receptors whereas memantine preferentially interacts with the NR2C and NR2D subunits (Monyer et al., 1994; Bresink et al., 1996 , Parsons et al., 1999 . When we tested the effect of Xe on NR2C
and NR2D containing NMDA receptors, we found that NR2C containing receptors were inhbited by 41.3 ± 2.7 % (n=9) and those with the NR2D subunit by 41.4 ± 3.7 % (n=9), Fig. 5 . Alltogether, our data, including those from the NR2A and NR2B
subunits indicate that the inhibitory potency of Xe is the same on either NR2 subunit. suggested that some of the mutated residues might either alter the access of the blocker to its binding site or disrupt the binding site by allosteric interactions (Kashiwagi et al., 2002) . Therefore, as our mutation is located in the extracellular vestibule, a well known target for channel blockers (Sobolevsky et al., 2002b) , we can not exclude a possible allosteric interaction of Xe with the ion pore.
Thus, also in this respect
Thus, our results enforce the question whether position 7 of the SYTANLAAF motif, located within transmembrane region 3 (TM3), represents a specific binding site for the noble gas Xe. Although none of the tested mutations per se had a prominent effect on Xe sensitivity, it can not totally be excluded that neither position 7 nor position 8 of the SYTANLAAF motif are important interaction sites for Xe with the NMDA receptor. The replacement of one alanine by cysteine might not be strong enough to eliminate this interaction in which probably several amino acids are involved. Alltogether, only the A-7-C mutants which undergo a strong modification by MTESA, loose their Xe sensitivity, whereas the other C substituted mutants which are not modified by MTSEA retain their Xe sensitivity.
Previously, other point mutations located within either TM3 of NR1 (F639A) or TM4 of NR2A (A825W) have also been described to partly reduce the sensitivity to Xe (Ogata et al., 2006) .These authors reasoned that either both subunits might contain complementary binding pockets for anesthetics, or as an alternative, that at least one of these sites might be involved in "transduction" rather than in binding of Xe (Ogata et al., 2006) . Both suggestions may also apply to our observations. First, the point mutations investigated here might affect transduction as they reside within the highly conserved SYTANLAAF motif which is assumed to be an important element of the NMDA receptor transducing ligand binding to channel opening (Wollmuth and Sobolevsky, 2004) . Second, anesthetic binding sites within amphiphilic cavities formed within the core of transmembrane domains have been postulated for GABA A R and glycine receptors (Jenkins et al., 2001; Bertaccini et al., 2005) . Very recently, the existence of a hydrophobic and flexible gas cavity as a possible binding site for Xe located within transmembrane domains of the NMDA receptor was deduced from crystallographic data of annexin V (Colloc'h et al., 2007) , considered to be a prototype for the NMDA receptor (Berendes et al., 1993; Demange et al., 1994) .
According to this model the binding of Xe within such a cavity would result in a volume expansion of the cavity thereby altering the flexibility of the pore and affecting receptor function (Colloc'h et al., 2007) . In this regard the modification of NR2A(A650C) or NR2B(A651C) by means of MTSEA, resulting in the introduction of a larger residue, might either directly hinder Xe to bind or to access its binding site.
Or, provided that the site of modification is close to the putative binding cavitiy, it might also prevent volume expansion of the cavity.
In conclusion, the receptor modification described here is appropriate to differentiate the inhibitory action of Xe from the actions of MK-801 and Mg 
